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Abstract
Purpose The recent publication of the ACOSOG Z1031
trial results demonstrated that Ki-67 proliferation marker-
based neoadjuvant endocrine therapy response monitoring
could be used for tailoring the use of adjuvant
chemotherapy in ER?HER2-negative breast cancer
patients. In this paper, we describe the development of the
Ki-67 clinical trial assay used for this study.
Methods Ki-67 assay assessment focused on reproducing a
2.7% Ki-67 cut-point (CP) required for calculating the
Preoperative Endocrine Prognostic Index and a 10% CP for
poor endocrine therapy response identification within the
first month of neoadjuvant endocrine treatment. Image
analysis was assessed to increase the efficiency of the
scoring process. Clinical outcome concordance for two
independent Ki-67 scores was the primary performance
metric.
Results Discordant scores led to a triage approach where
cases with complex histological features that software
algorithms could not resolve were flagged for visual point
counting (17%). The final Ki-67 scoring approach was run
on T1/2 N0 cases from the P024 and POL trials (N = 58).
The percent positive agreement for the 2.7% CP was 87.5%
(95% CI 61.7–98.5%); percent negative agreement 88.9%
(95% CI: 65.3–98.6%). Minor discordance did not affect
the ability to predict similar relapse-free outcomes (Log-
Rank P = 0.044 and P = 0.055). The data for the 10%
early triage CP in the POL trial were similar (N = 66), the
percentage positive agreement was 100%, and percent
negative agreement 93.55% (95% CI: 78.58–99.21%). The
independent survival predictions were concordant (Log-
rank P = 0.0001 and P = 0.01).
Conclusions We have developed an efficient and repro-
ducible Ki-67 scoring system that was approved by the
Clinical Trials Evaluation Program for NCI-supported
neoadjuvant endocrine therapy trials. Using the method-
ology described here, investigators are able to identify a
subgroup of patients with ER?HER2-negative breast
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cancer that can be safely managed without the need of
adjuvant chemotherapy.
Keywords Breast cancer  Biomarkers  Ki-67
proliferation marker
Introduction
Biomarkers of cell proliferation are used to assess prog-
nosis and response to cancer treatment, and most clinical
assays are based on Ki-67 immunohistochemistry (IHC)
[1]. The Ki-67 nuclear protein is present in proliferating
cells but absent in cells in G0 [2]. For breast cancer, Ki-67
analysis is relevant for estrogen receptor positive (ER?)
early stage breast cancer [3–5] which presents as a spec-
trum of tumors with clinically indolent (Luminal A) or
more aggressive features (Luminal B) [6]. While the ‘‘lu-
minal’’ classification is based on gene expression analysis,
a Ki-67 cut-point of 14% of cells staining positive has been
proposed as a surrogate for the distinction between luminal
A and luminal B [7]. This cut-point was considered clini-
cally useful by the St. Gallen breast cancer consensus panel
[8] but the concerns of the American Society of Clinical
Oncology Tumor Marker Guideline Committee regarding
the lack of rigor in Ki-67 scoring algorithms and the
questionable validity of decision-making cut-points has
slowed clinical implementation [9].
Ki-67 analysis also has potential for monitoring endocrine
therapy response, which requires testing a tumor specimen
after endocrine treatment has been initiated, for example, in
surgical specimens after neoadjuvant aromatase inhibition
[10]. The independent prognostic value of on-treatment Ki-67
was combined with pathologic tumor stage and ER status to
develop the preoperative endocrine prognostic index (PEPI).
A PEPI score of 0 (pT1/2N0, Ki-67 B2.7% and persistently
expressed ER) was associated with such favorable long-term
outcome after neoadjuvant endocrine therapy in the P024 trial
[11] and IMPACT trial [10, 12] that chemotherapy was
proposed to be unnecessary [13].
Recently, Ellis et al. published long-term follow-up
results of the ACOSOG Z1031 trial in which clinical
decisions were based on the PEPI score [14]. In ACOSOG
Z1031 Cohort B, the authors tested the hypothesis that Ki-
67-based algorithms can also address the concern that
patients who are poorly responsive to neoadjuvant endo-
crine therapy should ideally be identified early for triage to
alternate treatment, such as neoadjuvant chemotherapy or
immediate surgery. The authors also successfully identified
a subgroup of patients, based on PEPI scores that could be
safely spared from adjuvant chemotherapy. In this paper,
we describe the validation of Ki-67 cut-points relevant to
neoadjuvant endocrine treatment monitoring and the
development and validation of the Ki-67 clinical trial assay
for prospective studies, used in ACOSOG Z1031 trial [14].
Methods
Database analysis for early Ki-67 cut-point for early
triage to alternate treatment
Published data on research use only (RUO) quantitative
polymerase chain reaction (qPCR)-based assignments of
PAM50 luminal subtype (A vs. B) and RUO Ki-67 data
from TMA analysis was made available from six hundred
sixty-seven tumors with clinical ER-positive status from
University of British Columbia. Of these tumors, 358 were
classified as Luminal A and 309 as Luminal B [7]. Pub-
lished Ki-67 data and clinical outcomes from the IMPACT
trial [12] and POL Trial [15, 16] were used for the devel-
opment of cut-points for prospective validation.
Tumor samples for Ki-67 clinical trial assay
development
For training the scanner and image analysis-based Ki-67
quantification algorithm, 61 node-positive samples from
the P024 trial were examined. For assay validation for the
early triage cut-point, core needle biopsies taken after
4 weeks of neoadjuvant endocrine therapy from 66 patients
were accessed [15]. For validation of the 2.7% cut-point
required for the PEPI score, surgical specimens from 58
patients with pathological stage 1 or 2A tumors were
available from a combination of the POL trial [15] and the
P024 trial [11].
Ki-67 assay methodology
The research use only (RUO) Ki-67 assay employed to
stain the P024 and POL samples for combined survival
analysis employed the SP6 monoclonal antibody (Neo-
markers) on a Shandon Sequenza Immunostainer using
published methodology [13]. For the CLIA clinical trial
assay, 5 micron sections from POL and P024 trials were
subjected to H&E and Ki-67 staining in the CLIA-certified
Washington University AMP laboratory using the CON-
FIRM anti-Ki-67 (30-9) rabbit monoclonal primary anti-
body as a pre-diluted reagent on a Benchmark XT platform
according to the manufacturer instructions (Ventana, Tuc-
son, AZ). Tonsil was used as the assay control.
Ki-67 scoring approaches
For visual point counting (VPC), photomicrographs of
three randomly selected fields were taken at 40X with a
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background grid and color printed (more fields to achieve
the minimal cell count). Each observer counted both the
total number tumor cells and the number of Ki-67-positive
cells that intersect with first grid line. This process is
repeated on every third gridline. All the cells on the slide
were counted if three fields could not be obtained however
at least 200 total tumor cells were required. For Ki-67
image analysis of the CLIA clinical trial assay, slides were
scanned with the iScan Coreo scanner (Ventana). The
computer image was reviewed and ‘‘Areas of Interest’’
(AOI) were selected at 4X magnification using the fol-
lowing guidelines: (1) identify the largest AOI of repre-
sentative clear invasive tumor; (2) exclude DCIS, vessels,
lymphocytes; (3) avoid AOIs in peri-necrotic or necrotic
areas; (4) identify at least 3 AOIs and a maximum of 10.
The image analysis was performed using the FDA cleared
VENTANA Companion Algorithm Ki-67 (30-9) and the
VENTANA VIRTUOSO software (Roche).
Assessment of concordance
Two pathologists, blinded to each other’s data and any data
from earlier analyses of the samples, independently
reviewed the Ki-67 slide scans and identified AOI for either
image analysis or VPC methodology. Similarly blinded
trained technicians generated the VPC Ki-67 percentage.
Statistical analysis
Analysis of variance using a scatter-plot analysis was cal-
culated using Pearsons’ correlation and Spearman corre-
lation coefficients. Two pathologist concordance for the 2.7
and 10% cut-points were analyzed using four-by-four
contingency table analysis, simple Kappa coefficients and
percent positive and negative agreements. The prognostic
effect of modified PEPI 0 (pT1/2, N0, Ki-67 B 2.7%) vs.
non-0 assignments based on the CLIA Ki-67 assay deter-
mined using the Kaplan–Meier method. The log-rank test
was conducted to examine statistical significance. Similar
analyses were performed to correlate survival outcomes of
patients with early on-treatment Ki-67 ([10 vs B 10%) in
the POL trial. Bland–Altman plots were generated to assess
bias between pathologists.
Results
A Ki-67-based definition of poorly endocrine
therapy responsive tumors for triage to alternate
treatment
To develop a Ki-67-based approach for the early identifi-
cation of non-responders within a month of starting
treatment, we examined the interaction between baseline Ki-
67 levels and a qPCR-PAM50-based definition of luminal A
versus luminal B breast cancer using published data [17].
Using ROC methodology, a 10% Ki-67 cut-point of Ki-67
best served as a surrogate for the genomic luminal defini-
tions in this data set (Fig. 1). We therefore hypothesized that
tumors with an early Ki-67 value above 10% despite
endocrine therapy would be enriched for endocrine therapy
resistant, luminal B-type tumors with a high relapse rate.
This is supported by the early on-treatment data from the
POL [15] and IMPACT [12] trials which indicated that Ki-
67 levels[10% predicted a higher level of Ki-67 in the
surgical sample, a higher PEPI score, a smaller number of
patients in the PEPI-0 group, and worse RFS [14].
PEPI score validation and modification
Long-term outcomes from the POL trial provided an
opportunity to further validate of the PEPI score. While the
number of cases was modest, no relapses were observed in
10 patients with PEPI 0 tumors after a median follow-up of
59 months (Fig. 2a). We also developed a modified PEPI
score that did not include ER status at surgery, because of
clinical trial proposals that included the use of the estrogen
receptor down-regulator fulvestrant, the use of which con-
founds the interpretation of ER levels after treatment initi-
ation [18]. In the P024, IMPACT and POL trials, patients
with modified PEPI score of 0 were all ER? (Allred score
Fig. 1 ROC curve to determine the best Ki-67 cut-point to differ-
entiate Luminal A breast cancer from Luminal B breast cancer based
on a PAM50 qPCR RUO assay
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3–8) because ER Allred score 0–2 post aromatase inhibitor
or tamoxifen treatment was associated with either a high Ki-
67 or high tumor staging (or both) excluding these cases
from PEPI-0 status without the need for information on ER.
In the combined P024 trial/POL trial data, no relapses were
observed in the 29 patients (19 pT1N0, 10 pT2N0) with
modified PEPI-0 status (i.e., without scoring ER) during a
median follow-up of 62.5 months (Fig. 2b).
Validation of visual point counting (VPC)
for outcome prediction after neoadjuvant endocrine
therapy
In previous analyses, VPC methodology was routinely used
but this approach had not been formally assessed as part of a
clinical trial assay. Available surgical tumor samples from
pT1/2 N0 cases in the POL and P024 trials were therefore
stained using the commercial 30-9 antibody assay in a CLIA-
certified laboratory. Stage 1 or 2A cases were chosen because
a Ki-67 cut-point (CP) of B2.7% is the only factor that
determines the modified PEPI score of 0. The REMARK
sample flow chart for the duplicate study is provided in
Fig. 3a. Outcome predictions were reproducible, with no
relapses observed for patients assigned modified PEPI 0 (Ki-
67 B 2.7%) status by either pathologist (Fig. 3b). Analysis of
Ki-67 as a continuous variable indicated that the Spearman
Correlation Coefficient was 0.938 (p\0.0001) (Figure S2A),
and there was no trend for increased discordance across the
range of Ki-67 values (Figure S2B). The positive CP agree-
ment was 13/13 (100%). The negative agreement was 9/12
(0.75) (95% exact confidence limit: 0.428–0.945). Simple
Kappa Coefficient was 0.7573 (95% Confidence limit:
0.5073; 1) (Table 1, S1A).
Assessment of an image analysis approach for Ki-67
scoring
The performance of VPC, while technically adequate, is
laborious and therefore not ideal for real-time clinical
reporting. We therefore considered a Ki-67 scoring
approach using an FDA cleared scanner and image inter-
pretation software to determine if these tools were appro-
priate. For training, the 30-9 antibody-based commercial
assay was conducted on 61 surgical samples from patients
with node-positive disease in the P024 trial (Figure S1).
The slides were scanned and then analyzed by two
pathologists who independently reviewed the images and
drew areas of interest (AOI) for Ki-67 scoring. In five
instances, the algorithm did not accurately differentiate
between benign and malignant cells. These cases were
noteworthy for abundant lymphocyte infiltration, sparse
tumor cells where tumor cells were streaming through the
tissue with a large amount of intervening stroma, abundant
marking of non-fascicular ‘‘plump’’ fibroblasts, or when
the Ki-67 stain was generally diffuse and nuclear staining
was faint. Excluding these cases, the Spearman Correlation
Coefficient was 0.89 (p\ 0.0001) (Figure S3A). The
Bland–Altman plot showed no bias in scoring between the
two pathologists across the range of Ki-67 values (Fig-
ure S3B). The CP concordance was then analyzed. For the
2.7% cut-point, the positive agreement was 29/30 (0.96)
(95% exact confidence limit: 0.82–0.99). The negative
agreement was 23/26 (0.88) (95% exact confidence limit:
0.69–0.97). The kappa coefficient was 0.85 (95% confi-
dence limit: 0.71; 0.99). Using the 10% cut-point, the
positive agreement was 100%, and the negative agreement
was 46/47 (0.97) (95% exact confidence limit: 0.88–1). The
kappa coefficient was 0.93 (95% Confidence limit: 0.81;
1.0) (Table 1, S1B). A ‘‘locked-down’’ scoring standard
operating procedure (SOP) was generated that included an
Fig. 2 Kaplan–Meier curves showing relapse-free survival in the
POL trial (a) and in the combined data from the POL/P024 trials
using an RUO assay and VPC scoring methodology (b). PEPI
Preoperative endocrine prognostic index
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option to triage to VPC if the pathology was judged too
complex for the scanner to differentiate benign from
malignant cells (Fig. 4).
Validation of combined imaging/VPC Ki-67 scoring
SOP for the 2.7% Ki-67 cut-point
To validate the combined imaging/VPC SOP for Ki-67
scoring, the CLIA assay stained slides used for the VPC
assessment were scanned and independently assessed by
two pathologists. The sample flow chart is shown in
Fig. 5a. Kaplan–Meier analysis by modified PEPI 0 is
shown in Fig. 5b for the two separate scoring exercises.
Again, no relapses were observed in patients with modified
PEPI 0 during the follow-up using this scoring method
from either pathologist. Continuous data analysis indicated
that the Spearman Correlation Coefficient was 0.86
(p\ 0.0001) (Figure S4A). No scoring bias was observed
Fig. 3 a REMARK diagram showing sample flow through the study for validation of the visual point counting technique. b Kaplan–Meier
curves from two independent pathologists demonstrating relapse-free survival according to Ki-67 score[2.7 or B2.7%
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across the scored range (Figure S4B). The percentage
positive agreement between the two pathologists in scoring
the 2.7% CP Ki-67 using the SOP was 0.87 (95% CI
0.61–0.98). The negative agreement was 0.88 (95% CI
0.65–0.98). Simple kappa coefficient was 0.76 (95% CI
0.54–0.98) (Table 1, S1C).
Validation of combined imaging/VPC Ki-67 scoring
SOP for the 10% Ki-67 cut-point
To validate the combined imaging/VPC approach for the
10% cut-point one-month biopsies from the POL trial were
stained using the Ki-67 30-9 clinical trial assay, scanned,
and then independently reviewed for algorithm accuracy
and independently scored by two pathologists. The
REMARK sample flow chart is shown in Fig. 6a. Con-
cordant Kaplan–Meier analyses for the 10% cut-point for
two separate scoring exercises are shown in Fig. 6b. The
poor outcome for patients in the [10% category was
reproducible. The Spearman Correlation Coefficient was
0.86 (p\ 0.0001) (Figure S5A). No scoring bias was
observed across the scoring range (Figure S5B). The per-
centage positive agreement between the two pathologists in
scoring the 10% CP Ki-67 using the SOP was 100%. The
negative agreement was 93.6 (78.6–99.2). The kappa
coefficient was 0.86(0.66–1) (Table 1, S1D).
Discussion
We have developed an efficient and reproducible Ki-67
scoring system that was approved by the Clinical Trials
Evaluation Program (CTEP) for NCI-supported neoadju-
vant endocrine therapy trials. The combination of image
analysis with triage to VPC, when deemed necessary,
respects the finding that the image analysis software does
not always differentiate between certain types of normal
and malignant cells. This approach also emphasizes the
critical role of the pathologist in the review of the scanned
images to determine the most appropriate scoring approach
(image analysis or VPC) when the histology is complex.
The sample flow charts illustrate that while pathologists
may have different interpretations for the requirement for
visual point counting, these differences do not strongly
affect clinical outcome prediction. The VPC triage rate
Table 1 Summary of Ki-67 scoring agreement statistics according to the sample sets and different counting methods used
Sample set Ki-67 Cut-
point (%)
Counting method Percent positive
agreement (95% CI)
Percent negative
agreement (95% CI)
Kappa coefficient
(95% CI)
Validation set 2.7 Visual point counting 100 75 (42.8;94.5) 0.76 (0.51–1)
Training set 2.7 Virtuoso software 96.7 (82.8–99.9) 88.5 (69.9; 97.6) 0.85 (0.72;0.99)
10 Virtuoso software 100 97.9 (88.7;1) 0.94 (0.81;1)
Validation set 2.7 Ki-67 SOP 87.5 (61.7;98.5) 88.9 (65.3;98.6) 0.76 (0.55;0.98)
10 KI-67 SOP 100 93.6 (78.6;99.2) 0.86 (0.66;1)
Fig. 4 Standard operating procedure (SOP) for Ki-67 scoring with
the aid of an image scanner and the Companion Algorithm image
analysis software
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was, on average 17%, demonstrating that the image anal-
ysis approach can be used in the majority of cases, mark-
edly reducing the need to conduct laborious VPC to a
manageable number of cases. A weakness of our study is
that the sample sets were denuded by earlier analyses and
produced very modest sample sizes, and therefore, our
analysis did not produce evidence for immediate clinical
utility. However, the Ki-67 clinical trial assay developed
and described in this paper was further validated in
ACOSOG Z1031A study. In that trial, with a median
follow-up of 5.5 years, this Ki67 methodology was able to
identify a subgroup of patients with PEPI score = 0 (Ki-
67 B 2.7%, T1/2, N0) that were safely managed without
adjuvant chemotherapy. Among patients with PEPI = 0
score that were managed without chemotherapy, only 4 out
of 119 presented with a relapse during follow-up. The
triage rate to VPC in the Z1031A trial was 6%, even lower
than what we found in the POL and P024 sample sets.
An issue not addressed in the scoring algorithm pro-
posed herein concerns cases where the Ki-67 staining is not
Fig. 5 a REMARK diagram showing patient flow through the study for validation of the standard operating procedure for Ki-67 scoring.
b Kaplan–Meier curves from two independent pathologists demonstrating relapse-free survival according to Ki-67 score B2.7 or[2.7%
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uniform—our VPC or image analysis approach requires
random fields. We consider a Ki-67 heterogeneity-agnostic
approach equivalent to genomic approaches that also do
not clearly respect tissue heterogeneity. While analysis of
heterogeneity, or ‘‘Ki-67 hot spot’’ analysis, should be
pursued, this is a complex problem that will require the
development of a ‘‘hot-spot’’ definition that can be shown
to drive outcome more effectively than an analysis of all
the tumor cells in the section.
Another point of controversy is the Ki-67 cut-point as a
surrogate for luminal A versus luminal B breast cancer. In
our current analysis, 10% has the best operating charac-
teristics while an earlier publication on a different dataset
using similar methodology suggested 14% [7], which
suggests a narrow range of values for this purpose. From
the perspective of this paper, the 10% cut-point was more
conservative and serves the purpose of early identification
of patients with luminal B-type tumors with endocrine
therapy resistance characteristics well. The rapid onset of
advanced disease for patients with Ki-67[ 10% despite
aromatase inhibitor therapy (see Fig. 6b for example)
underscores the importance of developing a robust clinical
trial strategy for this high-risk population.
When we submitted our Ki-67 clinical trial assay to the
FDA they ruled the proposed treatment algorithms as ‘‘no
significant risk’’ because Ki-67 analysis actually reduces
the risk of under-treatment. This conclusion was based on
the analysis of chemotherapy use according to PEPI score
Fig. 6 a REMARK diagram showing patient flow through the study for validation of the standard operating procedure for Ki-67 scoring.
b Kaplan–Meier curves from two independent pathologists demonstrating relapse-free survival according to Ki-67 score B10 or[10% (b)
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shows that when medical oncologists rely on pathological
stage alone after neoadjuvant endocrine therapy most
patients with low stage do not receive chemotherapy.
Combined analysis of the P024, IMPACT and POL trials
showed that only 8% of patients with pathological stage 1
or 2A disease received adjuvant chemotherapy (Table S2).
Thus, the FDA considered that knowledge of the Ki-67
value in the pathological specimen reduced the risk of
under-treatment for patients with low pathological stage
tumors but aggressive biological characteristics (high on-
treatment Ki-67).
Even though ASCO still does not support Ki67 in its
clinical guidelines, a recent editorial acknowledges our
team’s efforts as ‘‘an important step in the direction of
clinical respectability for Ki67 as a useful breast cancer
prognosticator’’ [19]. The next necessary step is already
being taken as the Ki-67 clinical trial assay we described in
this paper is being prospectively validated in the
ALTERNATE trial (NCT01953588).
Acknowledgements We would like to thank Dr Lisa McShane for
guidance on the development plan for the Ki-67 assay, Dr Mitch
Dowsett and Dr Roger A’Hern for analysis of the IMPACT data and
Dr Torsten Nielsen for analysis of the University of British Columbia
tamoxifen series. We would also like to thank the FDA for their
review on the necessity of an IDE application for Ki-67 analysis in
CTEP sponsored neoadjuvant endocrine therapy trials.
Funding This work was supported by grants to Dr. Matthew Ellis
from the AVON Foundation, R01 CA095614, the Barnes-Jewish
Foundation, the Breast Cancer Research Foundation and Novartis (for
biomarker studies on the P024 trial). The tissue procurement core was
supported by NCI P50 CA68438. Dr R. Goncalves was supported by
the AVON foundation.
Compliance with ethical standards
Conflicts of interest Dr. Matthew Ellis has stock ownership of
Bioclassifier LLC and Prosigna Nanostring. Dr. Matthew Ellis
receives consultant fees from AstraZeneca, Novartis and Pfizer. Dr.
Michael Barnes is an employee and has stock ownership at Roche/
Ventana medical systems. The other authors declare that they have no
conflict of interest.
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Informed consent was obtained from all individual participants
included in the study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC,
Cuzick J et al (2011) Assessment of Ki67 in breast cancer: rec-
ommendations from the International Ki67 in Breast Cancer
working group. J Natl Cancer Inst 103(22):1656–1664
2. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a
mouse monoclonal antibody reactive with a human nuclear
antigen associated with cell proliferation. Int J Cancer
31(1):13–20
3. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA
(2010) Ki67 in breast cancer: prognostic and predictive potential.
Lancet Oncol. 11(2):174–183
4. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation
marker Ki-67 in early breast cancer. J Clin Oncol
23(28):7212–7220
5. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Prolif-
eration markers and survival in early breast cancer: a systematic
review and meta-analysis of 85 studies in 32,825 patients. Breast
17(4):323–334
6. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T
et al (2009) Supervised risk predictor of breast cancer based on
intrinsic subtypes. J Clin Oncol 27(8):1160–1167
7. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al
(2009) Ki67 index, HER2 status, and prognosis of patients with
luminal B breast cancer. J Natl Cancer Inst 101(10):736–750
8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B,
Senn HJ (2011) Strategies for subtypes–dealing with the diversity
of breast cancer: highlights of the St. Gallen International Expert
Consensus on the Primary Therapy of Early Breast Cancer 2011.
Ann Oncol 22(8):1736–1747
9. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S
et al (2007) American Society of Clinical Oncology 2007 update
of recommendations for the use of tumor markers in breast
cancer. J Clin Oncol 25(33):5287–5312
10. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R
et al (2007) Prognostic value of Ki67 expression after short-term
presurgical endocrine therapy for primary breast cancer. J Natl
Cancer Inst 99(2):167–170
11. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A,
Eremin J, Vinholes J et al (2001) Preoperative treatment of
postmenopausal breast cancer patients with letrozole: a random-
ized double-blind multicenter study. Ann Oncol 12(11):
1527–1532
12. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU
et al (2005) Neoadjuvant treatment of postmenopausal breast
cancer with anastrozole, tamoxifen, or both in combination: the
Immediate Preoperative Anastrozole, Tamoxifen, or Combined
with Tamoxifen (IMPACT) multicenter double-blind randomized
trial. J Clin Oncol 23(22):5108–5116
13. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS et al
(2008) Outcome prediction for estrogen receptor-positive breast
cancer based on postneoadjuvant endocrine therapy tumor char-
acteristics. J Natl Cancer Inst 100(19):1380–1388
14. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton
CJ et al (2017) Ki67 proliferation index as a tool for
chemotherapy decisions during and after neoadjuvant aromatase
inhibitor treatment of breast cancer: results From the American
College of Surgeons Oncology Group Z1031 Trial (Alliance).
J Clin Oncol. 35(10):1061–1069
15. Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ,
Fleming GF et al (2009) Improved surgical outcomes for breast
cancer patients receiving neoadjuvant aromatase inhibitor ther-
apy: results from a multicenter phase II trial. J Am Coll Surg
208(5):906–914 discussion 15-6
Breast Cancer Res Treat
123
16. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW et al
(2012) Whole-genome analysis informs breast cancer response to
aromatase inhibition. Nature 486(7403):353–360
17. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T
et al (2010) A comparison of PAM50 intrinsic subtyping with
immunohistochemistry and clinical prognostic factors in tamox-
ifen-treated estrogen receptor-positive breast cancer. Clin Cancer
Res 16(21):5222–5232
18. Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO,
Channon E et al (2013) A randomized trial to assess the bio-
logical activity of short-term (pre-surgical) fulvestrant 500 mg
plus anastrozole versus fulvestrant 500 mg alone or anastrozole
alone on primary breast cancer. Breast Cancer Res 15(2):R18
19. Sledge GW Jr (2017) Put Some PEPI in Your Step: Ki67’s Long
Road to Respectability. J Clin Oncol 35(10):1031–1032
Breast Cancer Res Treat
123
